Background
Autoimmune and Autoinflammatory Disorders, rheumatoid arthritis, PD, RA, SAD
AUTOIMMUNE DISORDERS, RHEUMATOID ARTHRITIS
Edited by: Alexandre Wagner Silva De Souza, Federal University of São Paulo, BrazilReviewed by: Devis Benfaremo, Marche Polytechnic University, Italy; Ajesh Maharaj, University of KwaZulu-Natal, South AfricaThis article was submitted to Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders, a section of the journal Frontiers in ImmunologyWBP216 is a novel human immunoglobulin G1 (IgG1) monoclonal antibody for interleukin (IL)-6. We aimed to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose (SAD) of WBP216 in patients with rheumatoid arthritis (RA).